Indications for ANAVIP:

Management of patients with North American rattlesnake envenomation.

Adults and Children:

Administer as soon as possible after rattlesnake bite at any signs of envenomation. Give by IV infusion over 60mins. First 10mins, proceed slowly at 25–50mL/hr rate; monitor for any allergic reaction. If no reaction occurs, increase to 250mL/hr rate until complete. Initially: 10 vials. Observe for ≥60mins after completion of infusion; if no response, repeat additional 10 vial doses every hour until initial control achieved. Once initial control achieved, monitor for ≥18hrs; may give additional 4 vial doses as needed if symptoms re-emerge.


Risk of anaphylactic reaction (esp. if allergic to horse protein). Discontinue and treat if anaphylaxis or hypersensitivity reactions occur. Monitor for delayed allergic reactions or serum sickness; treat appropriately if necessary. Obtain CBCs, platelets, PT/PTT, serum fibrinogen levels, and routine serum chemistries prior to initiation and periodically thereafter. Risk of transmitting infectious agents (eg, viruses). Allergy to cresol. Pregnancy. Nursing mothers.

Pharmacologic Class:


Adverse Reactions:

Pruritus, nausea, rash, arthralgia, peripheral edema, myalgia, headache, pain in extremity, vomiting, erythema; hypersensitivity reactions, serum sickness.

Generic Availability:


How Supplied:

Single-use vial—1